Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Renal Cell × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 17 Neoplasms 9 Polycystic Ovary Syndrome 7 Multiple Myeloma 4 Vomiting 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Melanoma 3 Leukemia, Myeloid, Acute 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Obesity 2 Nausea 2 Lung Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, B-Cell 2 Leukemia 2 Insulin Resistance 2 Inflammation 2 Colorectal Neoplasms 2 Cardiotoxicity 2 Weight Gain 1 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1

Interventions

Nivolumab 121 pembrolizumab 108 Sunitinib 100 Everolimus 60 Bevacizumab 58 Sorafenib 57 cabozantinib 56 pazopanib 53 Ipilimumab 51 Axitinib 46 aldesleukin 45 Magnetic Resonance Spectroscopy 38 Cyclophosphamide 34 Interferon-alpha 32 Interleukin-2 31 Radiosurgery 29 lenvatinib 27 Specimen Handling 26 temsirolimus 21 belzutifan 21 atezolizumab 21 fludarabine phosphate 18 Gemcitabine 18 Biopsy 16 fludarabine 15 avelumab 15 Interferon alpha-2 15 Radiotherapy 14 Paclitaxel 14 durvalumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡